Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of Albiglutide in Japanese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with a historical diagnosis of type 2 diabetes mellitus who is currently treated with diet and exercise only or one OAD~* BMI ≥18 kg/m2 and \<35 kg/m2 at Screening~* HbA1c between 7.0% and 10.0%, inclusive~* Fasting C-peptide ≥0.8 ng/mL (≥0.26 nmol/L)~* Female subjects of childbearing potential must be practicing adequate contraception .~* Able and willing to monitor his/her own blood glucose concentrations with a home glucose monitor.~* Able and willing to provide written informed consent~Exclusion Criteria:~* Diagnosis of type 1 diabetes mellitus~* Uncorrected thyroid dysfunction~* Previous use of insulin within one month prior to screening, or more than seven total days of insulin treatment within three months prior to screening~* Clinically significantly cardiovascular and/or cerebrovascular disease including, but not limited to the following:~  * Previous history of stroke or transient ischemic attack~ * Active, unstable coronary heart disease within the past six months before Screening~ * Documented myocardial infarction within one year before Screening~ * Any cardiac surgery including percutaneous transluminal coronary angioplasty, coronary stent placement, or coronary artery bypass graft surgery within one year before Screening~ * Unstable angina~ * Clinically significant arrhythmia or valvular heart disease~ * Current heart failure NYHA class II to IV~ * Resting systolic pressure \>160 mm Hg or diastolic pressure \>95 mm Hg at Screening~ * ECG criteria at Screening~* Heart rate: \<40 and \>110 bpm~* PR interval: \<120 and \> 210 msec~* QRS interval: \<70 and \>120 msec~* QTc interval (Bazett): \>450 msec or \>480 msec with bundle branch block~* Fasting triglyceride level \>400 mg/dL at Screening~* AST or ALT \>2xULN, ALP and bilirubin \>1.5xULN (except known Gilbert's syndrome and a fractionated bilirubin that shows conjugated bilirubin \<35% of total bilirubin)~* If female, is currently lactating, within 6 weeks post-partum, pregnant, or actively trying to become pregnant~* Has significant renal disease as manifested by one or more of the following:~  * Creatinine clearance at screening \<60 mL/min (calculated by Cockcroft-Gault formula) at Screening~ * Known loss of a kidney either by surgical ablation, injury or disease level~* A hemoglobinopathy that may affect determination of HbA1c level~* History of treated diabetic gastroparesis~* History of significant gastrointestinal surgery, including gastric bypass and banding, or surgeries thought to significantly affect upper gastrointestinal function~* Current ongoing symptomatic biliary disease or history of acute/chronic pancreatitis.~* Lipase and amylase at Screening \> ULN~* Severe diabetic neuropathy, preproliferative retinopathy or proliferative retinopathy, history of ketoacidosis or hyperosmolar coma~* History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 3 years before Screening. (A history of treated cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II is allowed)~* Acute or chronic history of liver disease, positive hepatitis B surface antigen (HBsAg) or positive hepatitis C testing at Screening~* Current and history of alcohol or substance abuse~* Clinically significant anaemia or any other abnormal haematological profile that is considered by the investigator to be clinically significant~* Prior use of a GLP-1 analog~* Known allergy to any formulation excipients, or Baker's yeast, or history of drug, or other allergy which, in the opinion of the responsible study physician, contradicts participation~* History of or family history of medullary carcinoma of the thyroid.~* History of or family history of multiple endocrine neoplasia type 2~* Receipt of any investigational drug within the 12 weeks before Screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- albiglutide 15mg weekly (Type: ACTIVE_COMPARATOR): once weekly subcutaneous injection of albiglutide 15mg
- albiglutide 30mg weekly (Type: ACTIVE_COMPARATOR): once weekly subcutaneous injection of albiglutide 30mg
- albiglutide 30mg every other week (Type: ACTIVE_COMPARATOR): subcutaneous injection of 30mg albiglutide every other week
- placebo (Type: PLACEBO_COMPARATOR): once weekly subcutaneous injection of placebo to match albiglutide

Based on this trial design, predict the completion outcome and termination type (if applicable).